Jagsonpal Pharmaceuticals Limited — Updates, 26-07-2025: Press Release (Revised)

Jagsonpal Pharma posted strong Q1FY26 results. Revenue surged 23.1% YoY to ₹75.6 Cr, driven by brand strength. Operating EBITDA jumped 24.1% to ₹15.7 Cr, with margins at 20.8%. Net profit more than doubled to ₹10.8 Cr. The company's cash position remains robust at ₹160.9 Cr, providing flexibility for future growth. Management highlights its strengthened #7 position in Gynae CVM and plans to deepen domestic market presence and explore strategic inorganic opportunities. The lean, asset-light model continues to support performance.